Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254)

Jonathan B Catterall, Thomas V Stabler, Carl R Flannery, Virginia B Kraus, Jonathan B Catterall, Thomas V Stabler, Carl R Flannery, Virginia B Kraus

Abstract

Introduction: Acute trauma involving the anterior cruciate ligament is believed to be a major risk factor for the development of post-traumatic osteoarthritis 10 to 20 years post-injury. In this study, to better understand the early biological changes which occur after acute injury, we investigated synovial fluid and serum biomarkers.

Methods: We collected serum from 11 patients without pre-existing osteoarthritis from a pilot intervention trial (5 placebo and 6 drug treated) using an intra-articular interleukin-1 receptor antagonist (IL-1Ra) therapy, 9 of which also supplied matched synovial fluid samples at presentation to the clinic after acute knee injury (mean 15.2 ± 7.2 days) and at the follow-up visit for reconstructive surgery (mean 47.6 ± 12.4 days). To exclude patients with pre-existing osteoarthritis (OA), the study was limited to individuals younger than 40 years of age (mean 23 ± 3.5) with no prior history of joint symptoms or trauma. We profiled a total of 21 biomarkers; 20 biomarkers in synovial fluid and 13 in serum with 12 biomarkers measured in both fluids. Biomarkers analyzed in this study were found to be independent of treatment (P > 0.05) as measured by Mann-Whitney and two-way ANOVA.

Results: We observed significant decreases in synovial fluid (sf) biomarker concentrations from baseline to follow-up for (sf)C-Reactive protein (CRP) (P = 0.039), (sf)lubricin (P = 0.008) and the proteoglycan biomarkers: (sf)Glycosaminoglycan (GAG) (P = 0.019), and (sf)Alanine-Arginine-Glycine-Serine (ARGS) aggrecan (P = 0.004). In contrast, we observed significant increases in the collagen biomarkers: (sf)C-terminal crosslinked telopeptide type II collagen (CTxII) (P = 0.012), (sf)C1,2C (P = 0.039), (sf)C-terminal crosslinked telopeptide type I collagen (CTxI) (P = 0.004), and (sf)N-terminal telopeptides of type I collagen (NTx) (P = 0.008). The concentrations of seven biomarkers were significantly higher in synovial fluid than serum suggesting release from the signal knee: IL-1β (P < 0.0001), fetal aggrecan FA846 (P = 0.0001), CTxI (P = 0.0002), NTx (P = 0.012), osteocalcin (P = 0.012), Cartilage oligomeric matrix protein (COMP) (P = 0.0001) and matrix metalloproteinase (MMP)-3 (P = 0.0001). For these seven biomarkers we found significant correlations between the serum and synovial fluid concentrations for only CTxI (P = 0.0002), NTx (P < 0.0001), osteocalcin (P = 0.0002) and MMP-3 (P = 0.038).

Conclusions: These data strongly suggest that the biology after acute injury reflects that seen in cartilage explant models stimulated with pro-inflammatory cytokines, which are characterized by an initial wave of proteoglycan loss followed by subsequent collagen loss. As the rise of collagen biomarkers in synovial fluid occurs within the first month after injury, and as collagen loss is thought to be irreversible, very early treatment with agents to either reduce inflammation and/or reduce collagen loss may have the potential to reduce the onset of future post-traumatic osteoarthritis.

Trial registration: The samples used in this study were derived from a clinical trial NCT00332254 registered with ClinicalTrial.gov.

References

    1. Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007;35:1756–1769. doi: 10.1177/0363546507307396.
    1. Frobell RB, Roos HP, Roos EM, Hellio Le Graverand MP, Buck R, Tamez-Pena J, Totterman S, Boegard T, Lohmander LS. The acutely ACL injured knee assessed by MRI: are large volume traumatic bone marrow lesions a sign of severe compression injury? Osteoarthritis Cartilage. 2008;16:829–836. doi: 10.1016/j.joca.2007.11.003.
    1. Roos EM. Joint injury causes knee osteoarthritis in young adults. Curr Opin Rheumatol. 2005;17:195–200. doi: 10.1097/01.bor.0000151406.64393.00.
    1. Gelber AC, Hochberg MC, Mead LA, Wang NY, Wigley FM, Klag MJ. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000;133:321–328.
    1. Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma. 2006;20:739–744. doi: 10.1097/01.bot.0000246468.80635.ef.
    1. Buckwalter JA, Saltzman CL, Brown T. The impact of osteoarthritis: implication for research. Clin Orthop Relat Res. 2004;427:S6–15. doi: 10.1097/01.blo.0000143938.30681.9d.
    1. Chaudhari AM, Briant PL, Bevill SL, Koo S, Andriacchi TP. Knee kinematics, cartilage morphology, and osteoarthritis after ACL injury. Med Sci Sports Exerc. 2008;40:215–222. doi: 10.1249/mss.0b013e31815cbb0e.
    1. Irie K, Uchiyama E, Iwaso H. Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee. 2003;10:93–96. doi: 10.1016/S0968-0160(02)00083-2.
    1. Lohmander LS, Atley LM, Pietka TA, Eyre DR. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 2003;48:3130–3139. doi: 10.1002/art.11326.
    1. Lohmander LS, Dahlberg L, Ryd L, Heinegard D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum. 1989;32:1434–1442. doi: 10.1002/anr.1780321113.
    1. Lohmander LS. The release of aggrecan fragments into synovial fluid after joint injury and in osteoarthritis. J Rheumatol Suppl. 1995;43:75–77.
    1. Lohmander LS, Hoerrner LA, Dahlberg L, Roos H, Bjornsson S, Lark MW. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol. 1993;20:1362–1368.
    1. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 1993;36:181–189.
    1. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993;36:1214–1222. doi: 10.1002/art.1780360906.
    1. Lohmander LS, Roos H, Dahlberg L, Hoerrner LA, Lark MW. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus. J Orthop Res. 1994;12:21–28. doi: 10.1002/jor.1100120104.
    1. Lohmander LS, Saxne T, Heinegard DK. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis. 1994;53:8–13. doi: 10.1136/ard.53.1.8.
    1. Dahlberg L, Roos H, Saxne T, Heinegard D, Lark MW, Hoerrner LA, Lohmander LS. Cartilage metabolism in the injured and uninjured knee of the same patient. Ann Rheum Dis. 1994;53:823–827. doi: 10.1136/ard.53.12.823.
    1. Carney SL, Billingham ME, Muir H, Sandy JD. Demonstration of increased proteoglycan turnover in cartilage explants from dogs with experimental osteoarthritis. J Orthop Res. 1984;2:201–206. doi: 10.1002/jor.1100020301.
    1. Ratcliffe A, Billingham ME, Saed-Nejad F, Muir H, Hardingham TE. Increased release of matrix components from articular cartilage in experimental canine osteoarthritis. J Orthop Res. 1992;10:350–358. doi: 10.1002/jor.1100100307.
    1. Kraus VB, Birmingham J, Stabler T, Taylor DC, Moorman CT, III, Garrett WE, Toth A. Intraarticular IL1-Ra after acute knee injury decreases biomarkers of inflammation and improves pain and function. Osteoarthritis Cartilage. 2010. in press .
    1. Swearingen CA, Chambers MG, Lin C, Marimuthu J, Rito CJ, Carter QL, Dotzlaf J, Liu C, Chandrasekhar S, Duffin KL, Mitchell PG, Durham TB, Wiley MR, Thirunavukkarasu K. A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs. Osteoarthritis Cartilage. 2010;18:1159–1166. doi: 10.1016/j.joca.2010.02.019.
    1. Stabler TV, Byers SS, Zura RD, Kraus VB. Amino acid racemization reveals differential protein turnover in osteoarthritic articular and meniscal cartilages. Arthritis Res Ther. 2009;11:R34. doi: 10.1186/ar2639.
    1. Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage. 2002;10:707–713. doi: 10.1053/joca.2002.0819.
    1. Flannery CR, Zollner R, Corcoran C, Jones AR, Root A, Rivera-Bermudez MA, Blanchet T, Gleghorn JP, Bonassar LJ, Bendele AM, Morris EA, Glasson SS. Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin. Arthritis Rheum. 2009;60:840–847. doi: 10.1002/art.24304.
    1. Kineret® (anakinra) (summary of product characteristics)
    1. Cawston TE, Ellis AJ, Humm G, Lean E, Ward D, Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun. 1995;215:377–385. doi: 10.1006/bbrc.1995.2476.
    1. Page Thomas DP, King B, Stephens T, Dingle JT. In vivo studies of cartilage regeneration after damage induced by catabolin/interleukin-1. Ann Rheum Dis. 1991;50:75–80. doi: 10.1136/ard.50.2.75.
    1. Thomas L. Reversible collapse of rabbit ears after intravenous papain, and prevention of recovery by cortisone. J Exp Med. 1956;104:245–252. doi: 10.1084/jem.104.2.245.
    1. Jubb RW, Fell HB. The breakdown of collagen by chondrocytes. J Pathol. 1980;130:159–167. doi: 10.1002/path.1711300304.
    1. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol. 2010;10:605–611. doi: 10.1038/nri2804.
    1. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 2000. pp. 175–183.
    1. Brown KK, Heitmeyer SA, Hookfin EB, Hsieh L, Buchalova M, Taiwo YO, Janusz MJ. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond) 2008;5:22. doi: 10.1186/1476-9255-5-22.
    1. Hui W, Litherland GJ, Jefferson M, Barter MJ, Elias MS, Cawston TE, Rowan AD, Young DA. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology (Oxford) 2010;49:2043–2053. doi: 10.1093/rheumatology/keq217.
    1. Barter MJ, Hui W, Lakey RL, Catterall JB, Cawston TE, Young DA. Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann Rheum Dis. 2010;69:2189–2198. doi: 10.1136/ard.2010.129197.
    1. Sverdrup FM, Yates MP, Vickery LE, Klover JA, Song LR, Anglin CP, Misko TP. Protein geranylgeranylation controls collagenase expression in osteoarthritic cartilage. Osteoarthritis Cartilage. 2010;18:948–955. doi: 10.1016/j.joca.2010.03.015.
    1. Lakey RL, Cawston TE. Sulfasalazine blocks the release of proteoglycan and collagen from cytokine stimulated cartilage and down-regulates metalloproteinases. Rheumatology (Oxford) 2009;48:1208–1212. doi: 10.1093/rheumatology/kep236.
    1. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434:644–648. doi: 10.1038/nature03369.
    1. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, Flannery CR, Kanki K, Wang E, Peluso D, Yang Z, Majumdar MK, Morris EA. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum. 2004;50:2547–2558. doi: 10.1002/art.20558.
    1. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther. 2008;10:R63. doi: 10.1186/ar2434.
    1. Catterall JB, Cawston TE. Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther. 2003;5:12–24. doi: 10.1186/ar604.
    1. van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage. 2010;18:605–612. doi: 10.1016/j.joca.2010.01.012.
    1. Kraus VB, Burnett B, Coindreau J, Cotrell S, Eyre DR, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegard D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis: OARSI FDA Osteoarthritis Biomarkers Working Group. Osteoarthritis Cartilage. 2010. in press .
    1. Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum. 2006;54:2496–2504. doi: 10.1002/art.21977.
    1. Mazieres B, Hucher M, Zaim M, Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2007;66:639–645. doi: 10.1136/ard.2006.059899.
    1. Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, Eastell R. Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res. 2001;16:556–564. doi: 10.1359/jbmr.2001.16.3.556.
    1. Catterall JB, Barr D, Bolognesi M, Zura RD, Kraus VB. Post-translational aging of proteins in osteoarthritic cartilage and synovial fluid as measured by isomerized aspartate. Arthritis Res Ther. 2009;11:R55. doi: 10.1186/ar2675.
    1. Cao J, Li S, Shi Z, Yue Y, Sun J, Chen J, Fu Q, Hughes CE, Caterson B. Articular cartilage metabolism in patients with Kashin-Beck Disease: an endemic osteoarthropathy in China. Osteoarthritis Cartilage. 2008;16:680–688. doi: 10.1016/j.joca.2007.09.002.
    1. Hasegawa M, Nakoshi Y, Tsujii M, Sudo A, Masuda H, Yoshida T, Uchida A. Changes in biochemical markers and prediction of effectiveness of intra-articular hyaluronan in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2008;16:526–529. doi: 10.1016/j.joca.2007.09.014.
    1. van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, Tak PP. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One. 2010;5:pii: 12556. doi: 10.1371/journal.pone.0012556.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren